What is HC Wainwright's Estimate for BCAX Q1 Earnings?

Key Points

• HC Wainwright forecasts Bicara Therapeutics will post a Q1 2027 loss of $1.11 per share and a full-year 2027 loss of $4.63 per share, with quarterly losses projected to widen through the year.
• The firm maintained its Buy rating but lowered its price target from $42 to $36. Analyst sentiment is mixed overall, with MarketBeat reporting a “Moderate Buy” consensus and a $30.33 average target.
• Bicara’s latest reported quarterly loss was $1.04 per share, missing the $0.82-per-share consensus estimate by $0.22.

Bicara Therapeutics Inc. (NASDAQ:BCAX - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2027 earnings per share (EPS) estimates for Bicara Therapeutics in a note issued to investors on Wednesday, November 11th. HC Wainwright analyst R. Burns anticipates that the company will post earnings per share of ($1.11) for the quarter. HC Wainwright has a "Buy" rating and a $36.00 price target on the stock. The consensus estimate for Bicara Therapeutics' current full-year earnings is ($3.58) per share. HC Wainwright also issued estimates for Bicara Therapeutics' Q2 2027 earnings at ($1.14) EPS, Q3 2027 earnings at ($1.17) EPS, Q4 2027 earnings at ($1.21) EPS and FY2027 earnings at ($4.63) EPS.

Several other brokerages have also issued reports on BCAX. The Goldman Sachs Group lowered shares of Bicara Therapeutics from a "neutral" rating to a "sell" rating and cut their target price for the stock from $20.00 to $8.00 in a research note on Friday, October 30th. Benchmark restated a "buy" rating on shares of Bicara Therapeutics in a report on Thursday, October 29th. Wedbush decreased their price target on shares of Bicara Therapeutics from $33.00 to $24.00 and set an "outperform" rating for the company in a research note on Thursday, October 29th. Cantor Fitzgerald reiterated an "overweight" rating on shares of Bicara Therapeutics in a report on Thursday, September 10th. Finally, Wells Fargo & Company increased their price objective on shares of Bicara Therapeutics from $16.00 to $23.00 and gave the stock an "equal weight" rating in a research report on Wednesday, August 12th. Two research analysts have rated the stock with a Strong Buy rating, eleven have given a Buy rating, three have issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and a consensus target price of $30.33.

Bicara Therapeutics Stock Up 3.4%

NASDAQ:BCAX opened at $10.53 on Thursday. The company has a fifty day moving average of $17.37 and a 200-day moving average of $20.84. The firm has a market capitalization of $696.80 million, a P/E ratio of -3.03 and a beta of -0.33. Bicara Therapeutics has a twelve month low of $7.87 and a twelve month high of $30.99.

Bicara Therapeutics (NASDAQ:BCAX - Get Free Report) last issued its quarterly earnings results on Monday, November 9th. The company reported ($1.04) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.82) by ($0.22).

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. Russell Investments Group Ltd. lifted its holdings in shares of Bicara Therapeutics by 33.3% in the third quarter. Russell Investments Group Ltd. now owns 44,425 shares of the company's stock worth $827,000 after buying an additional 11,086 shares in the last quarter. Nan Fung Trinity HK Ltd. grew its stake in Bicara Therapeutics by 49.9% during the third quarter. Nan Fung Trinity HK Ltd. now owns 427,885 shares of the company's stock valued at $7,963,000 after acquiring an additional 142,390 shares in the last quarter. Alps Advisors Inc. boosted its holdings in Bicara Therapeutics by 32.5% in the 3rd quarter. Alps Advisors Inc. now owns 87,692 shares of the company's stock valued at $1,632,000 after purchasing an additional 21,510 shares during the period. Mirae Asset Global Investments Co. Ltd. purchased a new position in shares of Bicara Therapeutics during the 3rd quarter valued at $63,000. Finally, Profund Advisors LLC grew its position in shares of Bicara Therapeutics by 7.2% during the 3rd quarter. Profund Advisors LLC now owns 16,880 shares of the company's stock valued at $314,000 after purchasing an additional 1,140 shares in the last quarter.

Insider Activity

In related news, CEO Ryan Cohlhepp sold 17,500 shares of the stock in a transaction dated Tuesday, September 8th. The shares were sold at an average price of $22.90, for a total transaction of $400,750.00. Following the completion of the transaction, the chief executive officer owned 181,641 shares in the company, valued at approximately $4,159,578.90. This represents a 8.79% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 13.80% of the stock is currently owned by corporate insiders.

Latest Bicara Therapeutics News

These are some of the BCAX news items that stood out recently:

• Positive Sentiment: HC Wainwright maintained its Buy rating and a $36 price target, indicating continued confidence despite lowering its target from $42. HC Wainwright recommendation
• Negative Sentiment: New headlines report that Stifel Nicolaus and Morgan Stanley cut their BCAX price targets, while BTIG Research issued a pessimistic stock-price forecast. Further target reductions may weigh on sentiment, even though prior reports showed these firms retained positive ratings. Stifel target cut Morgan Stanley target cut BTIG forecast
• Negative Sentiment: HC Wainwright forecasts a 2027 loss of $4.63 per share, with quarterly losses increasing from $1.11 in Q1 to $1.21 in Q4. That is a larger full-year loss than the cited current-year consensus estimate of $3.58 per share, highlighting continued cash-burning expectations. Bicara Therapeutics analyst coverage

Bicara Therapeutics Company Profile

Bicara Therapeutics is a clinical-stage biopharmaceutical company developing treatments for solid tumors. Its research focuses on therapies designed to target cancer cells while also addressing features of the tumor environment that can suppress immune responses. The company's lead investigational program, ficerafusp alfa (BCA101), is a bifunctional antibody designed to bind EGFR, a protein found on some tumor cells, and block TGF-beta, a signaling protein that can contribute to tumor growth and immune suppression.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.